Free tool
FAERS Monitor: Nizoral Anti-Dandruff
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020310 or its brand name (Nizoral Anti-Dandruff, Ketoconazole). Reports on generic versions are filed under their own applications.
Reports
17,634
Serious
9,513
54% of reports
Hospitalization
3,896
Death reported
1,123
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,779
- off label use1,268
- pruritus1,020
- fatigue1,005
- nausea897
- rash874
- diarrhoea838
- headache768
- pain753
- psoriasis663
- dyspnoea653
- dizziness632
- product use in unapproved indication600
- arthralgia593
- chronic kidney disease521
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 121 |
| 2005 | 131 |
| 2006 | 139 |
| 2007 | 132 |
| 2008 | 137 |
| 2009 | 265 |
| 2010 | 171 |
| 2011 | 321 |
| 2012 | 389 |
| 2013 | 362 |
| 2014 | 324 |
| 2015 | 923 |
| 2016 | 913 |
| 2017 | 941 |
| 2018 | 1,195 |
| 2019 | 1,367 |
| 2020 | 1,276 |
| 2021 | 1,193 |
| 2022 | 1,206 |
| 2023 | 1,804 |
| 2024 | 1,385 |
| 2025 | 1,601 |
| 2026 | 1,338 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,525 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 521 | 8.2 | 7.6 | 3,290 |
| psoriasisSignal | 663 | 6.1 | 5.6 | 2,813 |
| pruritusSignal | 1,020 | 3.2 | 3.0 | 1,538 |
| product use in unapproved indicationSignal | 600 | 2.9 | 2.7 | 748 |
| rashSignal | 874 | 2.4 | 2.2 | 722 |
| off label use | 1,268 | 1.7 | 1.6 | 405 |
| arthralgia | 593 | 1.7 | 1.6 | 174 |
| drug ineffective | 1,779 | 1.6 | 1.5 | 438 |
| diarrhoea | 838 | 1.5 | 1.5 | 168 |
| fatigue | 1,005 | 1.5 | 1.5 | 197 |
| dizziness | 632 | 1.5 | 1.4 | 112 |
| pain | 753 | 1.5 | 1.4 | 113 |
| headache | 768 | 1.5 | 1.4 | 115 |
| dyspnoea | 653 | 1.4 | 1.3 | 69 |
| nausea | 897 | 1.4 | 1.3 | 85 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.